Guggenheim Capital LLC Galectin Therapeutics Inc Transaction History

Guggenheim Capital LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$3.78 - $5.97 $39,274 - $62,028	-10,390 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$1.54 - $3.34 $1,998 - $4,335	-1,298 Reduced 11.11%	10,390 $35,000
Q3 2017 Nov 14, 2017	BUY	$1.67 - $2.3 $19,518 - $26,882	11,688	11,688 $25,000

9.36M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $167M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.